4//SEC Filing
Townsend Richard Nolan 4
Accession 0001415889-24-025110
CIK 0001907108other
Filed
Oct 14, 8:00 PM ET
Accepted
Oct 15, 1:45 PM ET
Size
9.5 KB
Accession
0001415889-24-025110
Insider Transaction Report
Form 4
Townsend Richard Nolan
DirectorChief Executive Officer
Transactions
- Exercise/Conversion
Common Stock
2024-10-10$2.33/sh+5,000$11,650→ 125,695 total - Exercise/Conversion
Stock Option (right to buy)
2024-10-10−5,000→ 123,655 totalExercise: $2.33Exp: 2031-02-15→ Common Stock (5,000 underlying) - Sale
Common Stock
2024-10-10$8.10/sh−5,000$40,496→ 120,695 total
Footnotes (4)
- [F1]The exercises and sales in this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 19, 2023.
- [F2]This transaction was executed in multiple trades at prices ranging from $7.99 to $8.3591. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
- [F3]Includes 43,750 restricted stock units (RSU's). Each RSU represents a contingent right to receive one share of Common Stock, subject to the applicable vesting schedule and conditions of each RSU.
- [F4]25% of the shares underlying the option vested on November 21, 2021, and 1/48th of the shares underlying the option vested or shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service.
Documents
Issuer
Lexeo Therapeutics, Inc.
CIK 0001907108
Entity typeother
Related Parties
1- filerCIK 0001995218
Filing Metadata
- Form type
- 4
- Filed
- Oct 14, 8:00 PM ET
- Accepted
- Oct 15, 1:45 PM ET
- Size
- 9.5 KB